Dr. Benjamin C. Powers, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 342
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KS license 04-35148 · MO license 2011011366
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- Mosaic Life Care at St Joseph Saint Joseph, MO
- University of Kansas Health System - St Francis Campus Topeka, KS
- Bothwell Regional Health Center Sedalia, MO
- St. Catherine Hospital - Garden City Garden City, KS
Medical groups
- University of Kansas Hospital Authority (250 clinicians)
- Ability Kc (167 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 342
- Services billed
- 1,098
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 275 | 159 |
| Established patient office or other outpatient visit, 30-39 minutes | 246 | 92 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 62 | 62 |
| New patient office or other outpatient visit, 60-74 minutes | 49 | 49 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 42 | 33 |
| Established patient office or other outpatient visit, 40-54 minutes | 32 | 26 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Overland PArk, KS | 48 |
| Eliquis (apixaban) Other prescribers in Overland PArk, KS | 35 |
| Levothyroxine Sodium Other prescribers in Overland PArk, KS | 32 |
| Gabapentin Other prescribers in Overland PArk, KS | 29 |
| Prednisone Other prescribers in Overland PArk, KS | 27 |
| Ibrance (palbociclib) | 27 |
| Imatinib Mesylate | 22 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Overland PArk, KS | 19 |
| Lorazepam Other prescribers in Overland PArk, KS | 17 |
| Omeprazole Other prescribers in Overland PArk, KS | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $81.43 in total to this clinician.
| AbbVie Inc. | $56.60 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $24.83 |
| Food and Beverage | $81.43 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $107,872 in research payments for these studies, mostly to the institutions running them.
- Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated lip…
Boehringer Ingelheim Pharmaceuticals, Inc. - Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals Inc. · Active, not recruiting · NCT03069469 - Brightline-4
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.